Brainstorm Cell (BCLI)

$0.84 -0.33 (-28.21%)
Market Cap 11.51M
Revenue (ttm) 0.00
Net Income (ttm) -11.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.16
Volume 819,600
Avg Vol 1,676,626
Day's Range N/A - N/A
Shares Out 9.84M
Stochastic %K 34%
Beta 0.22
Analysts Strong Sell
Price Target $7.50

Company Profile

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 488 0460
Address:
1325 Avenue of Americas, 28th Floor, New York, United States
ALSCellTherapy
ALSCellTherapy May. 16 at 6:15 AM
$BCLI ENDURANCE
0 · Reply
AshvsEvilDead
AshvsEvilDead May. 16 at 2:10 AM
$BCLI Dr. Houman for CBER. This needs to happen.
0 · Reply
ALSCellTherapy
ALSCellTherapy May. 15 at 10:14 PM
$BCLI On May 4, 2026, the Company entered into two additional private placement agreements with accredited investors, issuing an aggregate of 210,526 shares of Common Stock at $0.95 per share, together with warrants to purchase up to 252,630 shares of Common Stock at an exercise price of $1.45 per share, generating aggregate gross proceeds of $200,000. The proceeds are intended to support working capital and general corporate purposes. WHY WOULD INVESTORS PAY $.95 AND $1.45 IF SOMETHING WASN'T COMING?! THE STOCK WAS $.69 ON MAY 4, 2026.
3 · Reply
Knuckles30
Knuckles30 May. 15 at 8:21 PM
$BCLI DO NOT BELIEVE A WORD THE MAN SAYS
0 · Reply
CHItraders
CHItraders May. 15 at 8:14 PM
📊 Brainstorm Cell $BCLI Q1 Earnings ✅ Earnings Beat Adj. EPS: $(0.19) YoY: ↑ 57.78% (from $(0.45))
0 · Reply
afc2881
afc2881 May. 15 at 8:12 PM
$BCLI https://ir.brainstorm-cell.com/2026-05-15-BrainStorm-Cell-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update?printable=1
1 · Reply
AshvsEvilDead
AshvsEvilDead May. 14 at 7:59 PM
$BCLI Fastrack for Coya is great to see. Hopefully, maybe, FDA is starting to wake up with the recent rare disease scrutiny. This needs to be the number one priority for CBER to approve once they assign a new lead. Having Coya and Brainstorm options would be a dream come true for patients.
1 · Reply
SilentBull69
SilentBull69 May. 13 at 7:00 PM
$BCLI All of you “longs” here… do yourself a favor and go check out AMFN and ECOX back before I sold BCLI before the reverse split I tried to position you guys over to AMLX which was currently at three dollars then But a lot of folks are diehards and they are more interested in “hope”.. than they are reality I had a lot of hope for the ALS community too with BCLI But it’s just not happening … not with this company anyway If you’ve lost enough money and you need to build up your portfolio again ..like I said, go check out AMFN  You’re welcome ✌️
0 · Reply
Condo3e
Condo3e May. 13 at 4:54 PM
$BCLI Exosome Program Inside BrainStorm: $10M–$40M As a Spin‑Out: $40M–$120M Post‑Financing: $250M–$500M Strategic Acquisition: $500M–$1.5B Because the exosome program has: Top‑quartile IP GMP‑ready manufacturing Clean biology No regulatory baggage A booming market A suppressed valuation due to ALS overhang The value is trapped only because it sits inside BCLI.
1 · Reply
Cellsci
Cellsci May. 13 at 1:36 PM
$BCLI The exosome platform ? Man your really pushing it now, platform lol
1 · Reply
Latest News on BCLI
No data available.
ALSCellTherapy
ALSCellTherapy May. 16 at 6:15 AM
$BCLI ENDURANCE
0 · Reply
AshvsEvilDead
AshvsEvilDead May. 16 at 2:10 AM
$BCLI Dr. Houman for CBER. This needs to happen.
0 · Reply
ALSCellTherapy
ALSCellTherapy May. 15 at 10:14 PM
$BCLI On May 4, 2026, the Company entered into two additional private placement agreements with accredited investors, issuing an aggregate of 210,526 shares of Common Stock at $0.95 per share, together with warrants to purchase up to 252,630 shares of Common Stock at an exercise price of $1.45 per share, generating aggregate gross proceeds of $200,000. The proceeds are intended to support working capital and general corporate purposes. WHY WOULD INVESTORS PAY $.95 AND $1.45 IF SOMETHING WASN'T COMING?! THE STOCK WAS $.69 ON MAY 4, 2026.
3 · Reply
Knuckles30
Knuckles30 May. 15 at 8:21 PM
$BCLI DO NOT BELIEVE A WORD THE MAN SAYS
0 · Reply
CHItraders
CHItraders May. 15 at 8:14 PM
📊 Brainstorm Cell $BCLI Q1 Earnings ✅ Earnings Beat Adj. EPS: $(0.19) YoY: ↑ 57.78% (from $(0.45))
0 · Reply
afc2881
afc2881 May. 15 at 8:12 PM
$BCLI https://ir.brainstorm-cell.com/2026-05-15-BrainStorm-Cell-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update?printable=1
1 · Reply
AshvsEvilDead
AshvsEvilDead May. 14 at 7:59 PM
$BCLI Fastrack for Coya is great to see. Hopefully, maybe, FDA is starting to wake up with the recent rare disease scrutiny. This needs to be the number one priority for CBER to approve once they assign a new lead. Having Coya and Brainstorm options would be a dream come true for patients.
1 · Reply
SilentBull69
SilentBull69 May. 13 at 7:00 PM
$BCLI All of you “longs” here… do yourself a favor and go check out AMFN and ECOX back before I sold BCLI before the reverse split I tried to position you guys over to AMLX which was currently at three dollars then But a lot of folks are diehards and they are more interested in “hope”.. than they are reality I had a lot of hope for the ALS community too with BCLI But it’s just not happening … not with this company anyway If you’ve lost enough money and you need to build up your portfolio again ..like I said, go check out AMFN  You’re welcome ✌️
0 · Reply
Condo3e
Condo3e May. 13 at 4:54 PM
$BCLI Exosome Program Inside BrainStorm: $10M–$40M As a Spin‑Out: $40M–$120M Post‑Financing: $250M–$500M Strategic Acquisition: $500M–$1.5B Because the exosome program has: Top‑quartile IP GMP‑ready manufacturing Clean biology No regulatory baggage A booming market A suppressed valuation due to ALS overhang The value is trapped only because it sits inside BCLI.
1 · Reply
Cellsci
Cellsci May. 13 at 1:36 PM
$BCLI The exosome platform ? Man your really pushing it now, platform lol
1 · Reply
Cellsci
Cellsci May. 13 at 12:32 PM
$BCLI I think you mean promote him not hire him
0 · Reply
1968gibsongirl
1968gibsongirl May. 12 at 7:22 PM
$BCLI corporate update details? Time? Number?
0 · Reply
ALSCellTherapy
ALSCellTherapy May. 12 at 5:52 PM
$BCLI Makary out... https://www.politico.com/news/2026/05/12/makary-fda-resign-white-house-00916014
0 · Reply
Condo3e
Condo3e May. 12 at 11:31 AM
$BCLI THE STRATEGIC TRUTH The exosome platform is worth far more outside BrainStorm than inside it. A spin‑out (Path A) or platform license (Path B) unlocks 10× more value than internal development. BrainStorm’s ALS baggage suppresses the exosome platform’s valuation. Separating it instantly re‑rates the asset.
0 · Reply
Condo3e
Condo3e May. 12 at 11:26 AM
$BCLI Implication: Strong, long‑dated IP around what the exosomes are, how they’re made, and what indications they target. In IP terms, BrainStorm is top‑quartile among exosome players, especially in neuro.
1 · Reply
mfglola
mfglola May. 10 at 8:22 PM
$BCLI From WSJ editorial, "Instead, Dr. Makary looked on as Dr. Prasad drove out scientists who didn't share his mission of restricting access to drugs whose benefits he didn't think justified their costs." Cost is not supposed to be part of FDA's mission but may be a reason for the slow walk of the CP. Approved cell therapies are often a one time treatment unlike nurown....
2 · Reply
uieriwer
uieriwer May. 10 at 10:30 AM
$BCLI Investors, patients amd everyone deserves better than this.
1 · Reply
Condo3e
Condo3e May. 9 at 11:36 PM
$BCLI Folks, QNC, Quantum E Motion is a stock to investigate
0 · Reply
DoctorJT
DoctorJT May. 9 at 5:01 AM
$BCLI based upon Clene’s invitation from the FDA this week to file an AA NDA based upon their P2 Nfl data, anyone here think Coya goes the same route and gets invited to apply as well this year? For pALS I hope so, as Tregs appear to be the real deal in halting ALS progression. Coya has a real biotech CEO at the helm. Crazy that some of these companies may get approval on P2 data alone and Chaim couldn’t get it over the line with a P2 and P3 and is having to do yet another P3. Good ol’ Chaim.
2 · Reply
Condo3e
Condo3e May. 8 at 6:34 PM
$BCLI Bloomberg @business · President Donald Trump plans to fire Food and Drug Administration Commissioner Marty Makary, following months of chaos at one of the country’s most important health agencies, according to a person familiar with the matter.
0 · Reply
Condo3e
Condo3e May. 8 at 3:36 PM
$BCLI Apparently the year of Chaim is a second half of the year event
2 · Reply
Pipemajors82
Pipemajors82 May. 8 at 1:33 AM
$BCLI https://www.facebook.com/share/r/16fXGrrnSq/
0 · Reply